Lymphocytes, Activated

PreclinicalSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Lymphocytes, Activated is one of 74 small molecule programs targeting HIV. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIVTerminated

HIV-1 InfectionActive, not recruiting

HIVPreclinical

Terminated

HIV-1 InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

66 competitors in HIV-1 Infection

#DrugCompanyPhaseTrials

Tybost

Gilead

Approved

1 2

Epidiolex

Cabenuva

Taxol

Vemlidy

Emtriva

Crestor

Bayer Aspirin

Oncovin

Ziagen

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lymphocytes, Activated. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lymphocytes, Activated compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lymphocytes, Activated. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Lymphocytes, Activated

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV-1 infection1 trial

Immunotherapy1 trial

HIV1 trial

References

Drug Info

Quick Facts

Related News